The Exercise And Colorectal Cancer Treatment Trial (EXACT)

  • End date
    Apr 30, 2024
  • participants needed
  • sponsor
    Pennington Biomedical Research Center
Updated on 24 March 2022
aerobic exercise
stage iii colon cancer


This study will examine the biologic processes through which exercise may prevent disease recurrence in patients who have completed treatment for colorectal cancer.


This randomized trial will examine the biological effects of 12-weeks of moderate-intensity aerobic exercise versus wait-list control in 60 subjects who have completed standard medical therapy for colorectal cancer. The primary objective is to determine if aerobic exercise can reduce systemic inflammation, quantified using plasma concentrations of high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-alpha receptor two. The secondary objectives are to determine if exercise can reduce: 1) insulin resistance quantified using an oral glucose tolerance test, and; 2) circulating tumor cells quantified using a microfluidic antibody-mediated capture platform. The exploratory objective is to determine if exercise can improve mitochondrial respiration rates and fatty acid oxidation.

Condition Colon Cancer, Rectal Cancer
Treatment Wait-list control, Moderate-Intensity Aerobic Exercise
Clinical Study IdentifierNCT03975491
SponsorPennington Biomedical Research Center
Last Modified on24 March 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18 years
Histologically-confirmed stage I-III colorectal cancer
Completed surgical resection
Completed chemotherapy (if applicable)
Completed radiotherapy (if applicable)
Self-report, on average over the past one-month, less than or 90 minutes per week of moderate-intensity or vigorous-intensity physical activity
Provide written approval by physician or other qualified healthcare provider
No planned major surgery during the study period (including colostomy reversal; chemotherapy infusion port removal is permitted)
Readiness to exercise [as determined by a modified version the Physical Activity Readiness Questionnaire (PAR-Q)
Allow the collection and storage of specimens and data for future use 1.10 Willing to be randomized

Exclusion Criteria

Evidence of metastatic colon cancer
Concurrently actively treated other cancer (except non-melanoma skin cancer or in situ cancers)
Currently enrolled in another clinical trial of weight loss, physical activity, or dietary intervention
Current body mass greater than or equal to 181 kg
Unable to provide a baseline fasting blood sample
Unable or unwilling to give informed consent
Unable or unwilling to be randomized
Or any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (as determined by the investigative team)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note